Aratana Therapeutics (PETX) Receives Analyst Rating

Aratana Therapeutics (PETX) : Zacks Investment Research ranks Aratana Therapeutics (PETX) as 3, which is a Hold recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 5 research analysts is 1.4, which indicates as a Strong Buy.

Aratana Therapeutics (PETX) stock is expected to deviate a maximum of $3.16 from the average target price of $13 for the short term period. 6 Street Experts have initiated coverage on the stock with the most promising target being $18 and the most muted being $9.


Also, Lake Street assumes its rating on Aratana Therapeutics (NASDAQ:PETX). The global brokerage major announces a current price target of $15 per share. Analysts at the Lake Street have a current rating of Buy on the shares. The rating by the firm was issued on September 6, 2016.

Aratana Therapeutics (NASDAQ:PETX): After opening at $8.94, the stock dipped to an intraday low of $8.89 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $9.16 and the buying power remained strong till the end. The stock closed at $9.16 for the day, a gain of 1.89% for the day session. The total traded volume was 591,735. The stocks close on the previous trading day was $8.99.

Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions, such as pain and inflammation, stimulation of appetite, cancer and other serious diseases for dogs and cats. These product candidates are in various stages of development for the treatment of cats or dogs, or both. The Companys target indications include pain and inflammation associated with osteoarthritis, inappetence, post-operative pain, lymphoma, osteosarcoma, atopic dermatitis, ocular herpes and feline immunodeficiency virus. The Companys most advanced products from a development and commercialization perspective, AT-004 and AT-005, are monoclonal antibodies (MAbs) for treating lymphoma in dogs.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.